On our screens:Stocks with no debt
Is the price fair?
What WAT's price assumes
Waters Corporation trades at 101× earnings against 33.6× for the median Diagnostics & Research name, more expensive than its own group.
101
Trailing P/E · Diagnostics & Research median 33.6 · 2.99× the median: the market pays up for this one
- Price / sales
- 6.87
Price / sales · as of 2025-Q4
- Free cash flow yield
- 1.1%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +26%
Growth the price implies · The price pays for +26% free cash flow growth a year for a decade; revenue has grown +16% a year over the last three.
Details›
- Price / book2025-Q4
- 8.86
- EV / EBIT2025-Q4
- 27.9
- EV / sales2025-Q4
- 7.12
- Healthcare median P/E362 names
- 29.9
- Diagnostics & Research median P/E29 names
- 33.6
- Free cash flow, trailing twelve months
- $395M
- Market capitalisation
- $34.9B
- 3-year revenue growth
- +16%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $104.39 |
| Its own P/E history, median | $113.75 |
| Its own P/E history, upper quartile | $127.14 |
| 52-week range | $283.32 – $416.00 |
| Today | $403.07 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
The closest names by size in the same industry